Expression Analysis Data of BCL11A and γ-globin Genes in KU812 and KG-1 cell Lines After CRISPR/Cas9-mediated BCL11A Enhancer Deletion
Overview
Authors
Affiliations
The data presented in this article are related to the research article entitled as "Targeted deletion of the BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta-thalassemia disease " [1]. BCL11A is a master regulator of γ-globin gene silencing, and suppresses fetal hemoglobin expression by association with other γ-globin suppressors, and also interacts with human beta-globin locus control region as well as intergenic region between the Aγ and δ-globin genes to reconfigure beta-globin cluster. Thus, HbF reactivation has been proposed to be an approach for the treatment of β-thalassemia through knockout of BCL11A. Accordingly, an erythroid enhancer sequence was identified that, when inactivated, led to repression of BCL11A and induction of γ-globin in the erythroid lineage [2-7]. This article describes data that obtained from BCL11A gene enhancer modification in KU812 and KG-1 cell lines using the CRISPR-Cas9 genome editing system in order to reactivate γ-globin gene expression.
Ebrahimi S, Khosravi M, Raz A, Karimipoor M, Parvizi P Iran Biomed J. 2023; 27(5):219-46.
PMID: 37873636 PMC: 10707817. DOI: 10.61186/ibj.27.5.219.
Recent Advances in Genome-Engineering Strategies.
Boti M, Athanasopoulou K, Adamopoulos P, Sideris D, Scorilas A Genes (Basel). 2023; 14(1).
PMID: 36672870 PMC: 9859587. DOI: 10.3390/genes14010129.
Cosenza L, Zuccato C, Zurlo M, Gambari R, Finotti A Genes (Basel). 2022; 13(10).
PMID: 36292612 PMC: 9601852. DOI: 10.3390/genes13101727.
Samieyan Dehkordi S, Mousavi S, Ebrahimi M, Alizadeh S, Hedayati Asl A, Mohammad M Cell J. 2022; 24(2):76-84.
PMID: 35279963 PMC: 8918266. DOI: 10.22074/cellj.2022.7658.
Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing.
Asmamaw M, Zawdie B Biologics. 2021; 15:353-361.
PMID: 34456559 PMC: 8388126. DOI: 10.2147/BTT.S326422.